According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “
Separately, HC Wainwright reaffirmed a buy rating and set a $14.50 price objective on shares of Oxford BioMedica in a research report on Wednesday, September 4th.
Shares of OXBDF traded down $0.17 during trading hours on Thursday, reaching $6.82. 2,361 shares of the company traded hands, compared to its average volume of 5,618. The stock’s fifty day moving average is $8.12 and its 200 day moving average is $8.80. The stock has a market cap of $447.94 million, a P/E ratio of 45.47 and a beta of 0.79. Oxford BioMedica has a 1-year low of $6.89 and a 1-year high of $12.20.
Oxford BioMedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
Featured Article: CD Ladder
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.